Navigation Links
New Biologics Must Show Improvements in Efficacy, Safety and Cost-Benefit Compared with Currently Available Agents for Inclusion on Formularies in Argentina, Brazil and Mexico
Date:12/19/2013

BURLINGTON, Mass., Dec. 19, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that novel biologics must demonstrate improvements in efficacy, safety and cost-benefit compared with currently listed agents for a given disease to be included on both national and institutional formularies in Argentina, Brazil and Mexico. According to the new Strategic Insights report entitled Trends in Reimbursement of Biologics Across the Growth Markets: Focus on Argentina, Brazil and Mexico, numerous novel biological agents are in late-stage development for a range of oncology indications, rheumatoid arthritis and diabetes, and could reach these markets in the next two to three years.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The report notes that the market for biologics is lucrative, and growth in this sector will outpace the overall oncology and rheumatoid arthritis drug markets, resulting in an increase share of biologics in these markets.

"While approval from the regulatory bodies of Argentina, Brazil and Mexico may be reached shortly after a drug's approval in the major pharmaceutical markets, it may precede inclusion on formularies in these markets by several years," said Decision Resources Group Analyst Natalia Reoutova, M.A., M.Sc. "Historically, authorization was sufficient for market access terms but today, it's only one step toward favorable market access."

About Strategic Insights
Strategic Insights is a new series of high-level, strategic rep
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Synthetic Biologics Announces Exercise of Underwriters Over-Allotment Option
2. Synthetic Biologics Announces Proposed Public Offering of Common Stock
3. Synthetic Biologics SYN-004 for the Prevention of C. difficile Infections Named a "Top Project to Watch" by Elsevier Business Intelligence
4. Synthetic Biologics Reports Third Quarter 2013 Financial Results and Operational Update
5. Synthetic Biologics to Report Third Quarter 2013 Financial Results
6. Sanofi Adopts Genedata Biologics for Integrated Biopharma R&D Process Support
7. Samsung BioLogics unterzeichnet strategische Herstellungspartnerschaft mit Roche
8. Biosimilars Need Same Names as Original Biologics, Hospira Says at World Health Organization (WHO) Meeting
9. Samsung BioLogics Signs a Strategic Manufacturing Partnership with Roche
10. Gallus Strengthens Biologics CMO Business with Acquisition of Laureate
11. Synthetic Biologics Responds to Recent CDC Report on Threat of "Super Bugs"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... CHICAGO , Aug. 1. 2014 As ... U.S., the 2014 AACC Annual Meeting & Clinical Lab ... testing and patient care are introduced to the healthcare ... by the Expo,s 650 exhibitors will include the latest ... Advances in smartphones and biosensors have enabled ...
(Date:8/1/2014)... 2014 The  PROPEL Center  of the  iBIO ... rate of early-stage life sciences companies in ... 15 grants to help Illinois ...   in Chicago .   AdvaMed ... North America , bringing more than 1,000 ...
(Date:8/1/2014)... Once a decision has been made to increase ... how to define your tolerance for lowest cost design ... Director of Facilities Integration at Fluor Industrial Services, Craig ... and special guest Carrier Li, Director in Global Asset ... provide an examination of the Conceptual Design process and ...
(Date:8/1/2014)... Glencoe Software, Inc. is pleased ... ( http://glencoesoftware.com/data-inpress.html ), a suite of data ... into on-line publications.  The suite comprises Glencoe ... Photo - http://photos.prnewswire.com/prnh/20140731/132410   ... The DataViewer is a browser-based ...
Breaking Biology Technology:Lab-on-a-Chip Technology to Be Featured at 2014 AACC Annual Meeting & Clinical Lab Expo 2Lab-on-a-Chip Technology to Be Featured at 2014 AACC Annual Meeting & Clinical Lab Expo 3iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 2iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 3iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 4Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2Glencoe Software Launches Data InPress 2Glencoe Software Launches Data InPress 3
... (Nasdaq: PPHM ), a clinical stage biopharmaceutical,company developing ... virus (HCV) infection, today announced that it will release ... 2008 on March 11,2008 at 7:00 a.m. EDT and ... results at 11:30 a.m. EDT on the same day., ...
... (Nasdaq,CM: INSM), a developer of follow-on biologics and biopharmaceuticals, today,reported results for ... and Recent Company Highlights, -- Follow-on Biologics Program ... Factor or G-CSF) ... products to enter clinical trials in 2008; ...
... Vical Incorporated,(Nasdaq: VICL ) today announced ... Officer, will participate in a roundtable discussion,"An Industry ... in,Global Health Product Development," and present an overview ... on Tuesday,March 11, at the Biotechnology Industry Organization ...
Cached Biology Technology:Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results 2Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 2Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 3Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 4Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 5Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 6Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 7Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 8Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 9Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 10Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 11Vical to Present at BIO and BVGH Global Health Partnering Event 2Vical to Present at BIO and BVGH Global Health Partnering Event 3
(Date:7/31/2014)... beneath many of the roughly 156,000 gas stations ... corrosion in parts of underground gas storage tankscorrosion ... of groundwater, a source of drinking water. In ... reported many rapidly corroding gas storage tank components ... associated with use of gasoline-ethanol blends and the ...
(Date:7/31/2014)... protected 100 percent of animal models against the highly ... causes an intestinal disease that kills approximately 30,000 Americans ... Infection and Immunity . , In the ... against the purified toxins produced by C. difficile ... a laboratory model that mimics the human disease, after ...
(Date:7/31/2014)... An important step has been made to help better identify ... both an abnormal narrowing and enlarging of medium sized arteries ... kidneys and other organs causing damage. In a new report ... Journal , scientists provide evidence that that FMD may ... addition, they show a connection to abnormalities of bones and ...
Breaking Biology News(10 mins):NIST corrosion lab tests suggest need for underground gas tank retrofits 2C. difficile vaccine proves safe, 100 percent effective in animal models 2Scientists discover biochemical mechanisms contributing to fibromuscular dysplasia 2
... A method to detect contaminants in municipal water supplies ... Laboratory researchers whose findings are published on line in ... demonstrates that the technology that uses algae as sentinels ... Miguel Rodriguez Jr. and Elias Greenbaum of the Department ...
... Calif., August 27, 2009 -- Researchers at Burnham ... Southwestern Medical Center and University of Maryland have ... many bacteria can be targeted to kill dangerous ... can inhibit this enzyme and suppress the growth ...
... A new candidate gene for Specific Language Impairment has ... Rice at the University of Kansas, in collaboration with ... Gayn of Neocodex, Seville, Spain. The finding, reported in ... Disorders , was discovered by examining genes previously identified ...
Cached Biology News:ORNL scientists hone technique to safeguard water supplies 2The path to new antibiotics 2Researchers report gene associated with language, speech and reading disorders 2
DDO Immunogen: DDO (NP_003640, 270 a.a. ~ 370 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
... Immunogen: Goats were immunized ... Antibody was isolated by affinity chromatography using ... anti- human T7 affinity purified antibodies were ... method. Specificity: Antibody ...
Recognizes the VZV nucleocapsid by indirect immunofluorescence and immunoprecipitation. Shows cross-reactivity to HSV....
Duck polyclonal to Cobra venom - Fab Fragment ( Abpromise for all tested applications). Antigen: Snake Venom of N. naja arta...
Biology Products: